[HT-01] ホットトピックス01

[HT-01-2] TRAILBLAZER-ALZ-4: Comparing donanemab to aducanumab in early, symptomatic Alzheimer's disease

Stephane Epelbaum¹, Stephen Salloway², Elly Lee³, Michelle Papka⁴, Andrew Pain¹, Ena Oru¹, Margaret B. Ferguson¹, Hong Wang¹, Michael Case¹, Ming Lu¹, Emily C. Collins¹, Dawn A. Brooks¹, John Sims¹ (1.Eli Lilly and Company, 2.Department of Neurology and Department of Psychiatry, Alpert Medical School of Brown University; Butler Hospital, 3.Irvine Clinical Research, 4.The Cognitive and Research Center of New Jersey LLC)

As a neurologist mentored by Pr Bruno Dubois who transformed the concept of Alzheimer’s disease (AD) from that of an unspecific dementia to a precise clinico-biological entity I have been at the forefront of the clinical AD research field for the last 15 years. I participated to more than 30 clinical trials and was also part of the Aramis lab in which I contributed to neurodegenerative diseases digital modelling. I published more than 100 original articles in the field of AD and related disorders focusing on timely and accurate diagnosis of AD and new therapeutic options. In 2018 I was awarded the French Fondation Alzheimer prize for my clinical research. Since November 2021, I lead the medical affairs neurology team in the international business unit of Eli Lilly and Company working to bridge the gap between clinical development of innovative treatments and their implementation in clinical practice.